Oncology · 1 h ago
Post-chemotherapy CA19-9 and DUPAN-2 levels stratify survival in locally advanced pancreatic cancer
An author reflection describes a study of patients with initially unresectable locally advanced pancreatic ductal adenocarcinoma who ultimately underwent curative-intent surgery. Survival differed according to CA19-9 and DUPAN-2 levels measured after induction chemotherapy, but the cohort does not show whether surgery benefits patients with particular marker profiles.
- Post-chemotherapy marker grouping, but not baseline grouping, separated survival.
- Persistent elevation of both markers predicted poorer survival.
- The cohort included only patients who underwent resection.
The authors report findings from a cohort of patients with initially unresectable, locally advanced pancreatic ductal adenocarcinoma who underwent curative-intent resection. Patients were grouped using CA19-9 thresholds of 37 U/mL and DUPAN-2 thresholds of 150 U/mL, assessed before and after induction chemotherapy. The reflection does not report the cohort size.
Marker grouping before chemotherapy did not distinguish survival, whereas grouping after chemotherapy did. Patients whose levels of both markers remained elevated had a median survival of 1.4 years; all died within two years. Persistent elevation of both markers was independently associated with poorer survival (hazard ratio 7.22).
The findings suggest prognostic stratification among patients who reach surgery, not evidence that surgery improves outcomes for any marker-defined group. Because the cohort excluded patients who did not undergo resection, the authors call for multicenter research that includes them. The available report provides no sample size or further details on study methods.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Annals of Surgical Oncology: ASO Author Reflections: Assessment of Malignant Potential in Initially Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma by Combining CA19-9 and DUPAN-2 Levels ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.